Brucellosis Vaccines Market Size to Attain USD 389.50 Mn by 2033

The global brucellosis vaccines market size was estimated USD 242.70 million in 2023 and is expected to expand USD 389.50 million by 2033 growing at a CAGR of 4.84% from 2024 to 2033.

Brucellosis Vaccines Market Key Takeaways

The North America brucellosis vaccines market size reached USD 104.36 million in 2023 and is expected to surpass around USD 167.49 million by 2033.
North America has dominated the market with revenue share of 43% in 2023.
By application, in 2023, the cattle segment has accounted 57% revenue share in 2023.
By type, the RB51 vaccine segment dominated the market with revenue share of 43% in 2023.
By Vaccine Type, the DNA Vaccines segment has captured 32.5% revenue share in 2023.
By distribution channel, the public segment had the largest market share in 2023.

Brucellosis Vaccines Market Size 2024 to 2033

The brucellosis vaccines market revolves around the development, production, and distribution of vaccines aimed at preventing brucellosis, a zoonotic disease that affects both humans and animals. The disease is caused by bacteria of the genus Brucella, and it can lead to various health complications such as fever, joint pain, and fatigue in humans. In animals, it can cause reproductive issues and loss of productivity. Vaccination is one of the most effective measures to control and prevent the spread of brucellosis, making the brucellosis vaccines market essential for maintaining public health and animal welfare.

Get a Sample: https://www.precedenceresearch.com/sample/4113

Growth Factors
Several factors contribute to the growth of the brucellosis vaccines market. These include an increasing awareness of the disease and its impact on human and animal health, the growing need for effective control measures in livestock, and government initiatives to curb the spread of the disease. Additionally, the expansion of the livestock industry and the rising demand for animal-derived food products further drive the market, as farmers and producers aim to protect their animals and maintain food safety.

Regional Insights
The market for brucellosis vaccines varies across different regions. In areas where agriculture and livestock farming are prevalent, such as North America, Europe, and parts of Asia, the demand for brucellosis vaccines is higher. These regions prioritize disease prevention and control due to the economic impact of livestock health on their agricultural sectors. In contrast, developing regions may face challenges in accessing vaccines due to limited infrastructure and funding.

Drivers
Key drivers for the brucellosis vaccines market include the need to protect livestock health and productivity, which in turn ensures the safety of food supplies. Moreover, the risk of human infection from close contact with infected animals or animal products drives the demand for effective vaccination strategies. Government regulations and policies aimed at controlling brucellosis also play a significant role in market growth.

Opportunities
The brucellosis vaccines market presents opportunities for innovation in vaccine development, such as the creation of more effective and long-lasting vaccines. Additionally, there is potential for expanding market reach through partnerships with governments and organizations focused on public health and agriculture. Research and development in brucellosis vaccines can also lead to the discovery of novel therapeutic approaches.

Challenges
The market faces several challenges, including limited access to vaccines in low-resource settings, potential side effects or safety concerns, and the need for effective distribution networks. Additionally, the complexity of brucellosis as a disease, with multiple strains and species of Brucella, poses challenges for vaccine development and efficacy. Addressing these challenges is essential for ensuring the successful control and prevention of brucellosis.

Brucellosis Vaccines Market Recent Developments

In March 2024, Boehringer Ingelheim, a renowned player in the animal health sector, collaborated with Square Pharmaceuticals to launch Aftovaxpur in Bangladesh. This advanced foot-and-mouth disease (FMD) vaccine is specifically formulated for ruminants, including cattle and sheep, aiming to enhance livestock health in the region.
In October 2023, Zoetis, a leading animal health company based in the US, made headlines by acquiring Semex, a Canadian company specializing in bovine genetics and reproductive technology. This strategic move aims to bolster Zoetis’ standing in the cattle health market, particularly by enhancing its brucellosis vaccine offerings. The acquisition brings valuable expertise and a robust distribution network from Semex, strengthening Zoetis’ position in cattle breeding management.
In April 2023, Cornell University College of Veterinary Medicine (CVM) scientists researched and developed a novel diagnostic test to identify Brucella canis. This test helps in the early diagnosis of this zoonotic disease, which can spread to humans through contact with infected dogs. This will boost vaccination over time.
In July 2023, A notable development came from Hester Biosciences, an animal health company in India, with the launch of a new oral brucellosis vaccine for cattle. This innovative vaccine, based on the Brucella Abortus B19 strain, offers a more convenient and potentially cost-effective alternative to traditional injection-based vaccines. The introduction of this oral vaccine could open up new market segments, particularly in regions with limited resources, such as India.